KNC 6

Drug Profile

KNC 6

Latest Information Update: 31 Jul 2006

Price : $50

At a glance

  • Originator Kopran Research Laboratories
  • Class Antiulcers; Benzimidazoles
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Peptic ulcer

Most Recent Events

  • 31 Jul 2006 No development reported - Phase-I for Peptic ulcer in India (unspecified route)
  • 13 Oct 2002 Phase-I clinical trials in Peptic ulcer in India (unspecified route)
  • 27 Aug 2002 Preclinical trials in Peptic ulcer in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top